Massive bleeding is one of the leading causes of death in severe trauma. Evidence is growing suggesting that transfusion of whole blood is most appropriate in these cases, but the availability of blood group 0 whole blood with low levels (titers) of anti-A/B antibodies is limited. Thus, products/methods for the manufacturing of low titer-blood group 0 whole blood for use in massive transfusion may prove to be of significant clinical value in both civilian and military contexts.
The company's UBP product has been tested for this very purpose, to remove anti-A/B antibodies from blood group 0 whole blood, and the results will be presented as poster presentations around September 22-25 (SABM) and October 17-19 (AABB). In connection with each congress, abstracts of the results will also be published in two medical journals: "Anesthesia and Analgesia" and "Transfusion".
The ambition of the company's pre-launch of the UBP product is, as previously announced, to allow well-selected leading centers to evaluate the product. Published results will create a platform for a wider launch.
The information was submitted for publication, through the agency of the contact person, on July 19, 2021 08:00 CET.
Johan Nilsson, Interim CEO, Glycorex Transplantation AB.
Brief information about the company
Glycosorb® ABO is one of Glycorex Transplantation AB's self-developed proprietary medical devices that is used clinically in four continents to facilitate blood group-compatible transplants, especially in kidney transplants from related living donors, but the product is also used in liver, heart, lung and stem cell transplantation. The product has so far been used in more than 5,000 kidney transplants. The short-term and long-term results are excellent. The results have been presented in over 60 scientific articles in reputable medical journals. Each kidney transplant has been estimated to save up to SEK 5 million in dialysis costs alone. Each kidney transplant saves about 150 dialysis treatments per year, meaning that the over 5,000 kidney transplants performed after Glycosorb® treatments, can be estimated to save over 700,000 dialysis treatments per year. In addition to Europe, the product is used in India, Canada, Israel, Singapore, Thailand, Mexico and Australia, for example.
The company has also developed a CE-marked medical device for the development of universal blood plasma and are developing products for the specific reduction of autoantibodies in the treatment of autoimmune diseases, as well as products for specific reduction of galectins. The company also develops products for the simultaneous reduction of blood group A/B specific antibodies and HLA antibodies (tissue-specific antibodies). The company is collaborating with a leading European research institute to develop a product for the treatment of the autoimmune disease rheumatoid arthritis. There are approximately 5 million patients in the EU who have this disease.
Glycorex Transplantation AB (publ) is listed on NGM Main Regulated Equity (Nordic Growth Market) and is traded under the symbol GTAB B.